Home › Breast Cancer › NCT02610426

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

Exploratory Next Generation Sequencing to Identify Causative Variants for Therapy-Induced Congestive Heart Failure From Breast Cancer Study E5103 Germline DNA Samples

Who can join

All ages · All sexes

Inclusion Criteria:

* European American patients with DNA available
* European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab
* African American cases (based on a drop in left ventricular ejection fraction \[LVEF\] \< 50 or a drop from baseline \> 20 points) and African American controls

About the study

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving therapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with congestive heart failure receiving therapy for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to congestive heart failure.

What is being tested

• Laboratory Biomarker Analysis (other)

Sponsor: National Cancer Institute (NCI) · Participants: 162 · Started: Mar 25, 2014

Contact the study team

Official record on ClinicalTrials.gov — NCT02610426

Locations in the U.S.

Conditions

• Breast Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.